[ad_1] CFOTO | Future Publishing | Getty Images Pfizer on Thursday said its combination vaccine candidates targeting Covid and the flu will move to a final-stage trial in the coming months after showing positive initial results in an early to mid-stage study. That moves the pharmaceutical giant and its German partner BioNTech one step closer…
[ad_1] A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial results suggest that GSK’s shot, known as Arexvy, could help protect a wider population from RSV, a disease that causes thousands of hospitalizations and…
[ad_1] A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Patrick Van Katwijk | Getty Images Americans can finally get their hands on Novavax‘s newest Covid vaccine after U.S. regulators greenlighted the shot this…
[ad_1] A vial labelled “Novavax V COVID-19 Vaccine” is seen in this illustration taken January 16, 2022. Dado Ruvic | Reuters The Food and Drug Administration on Tuesday authorized Novavax‘s updated Covid vaccine for emergency use in people ages 12 and up, putting the shot on track to roll out weeks after new jabs from…
[ad_1] A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease Control and Prevention on Friday recommended Pfizer‘s maternal vaccine that protects infants from respiratory syncytial virus, putting the shot on track to be available in the U.S. this…
[ad_1] Pharmacist Ani Martirosyan administers an immunization to a patient at a CVS on Tuesday, Sept. 12, 2023 in Glendale, CA. Brian Van Der Brug | Los Angeles Times | Getty Images The rollout of a new round of Covid vaccines in the U.S. is off to a bumpy start as some patients report delays…
[ad_1] A nurse prepares a flu shot at Huntington Village Pediatrics, in Huntington, New York on December 8, 2021. Steve Pfost | Newsday | Getty Images Moderna on Wednesday said its experimental mRNA-based flu vaccine produced a stronger immune response against four strains of the virus than a currently available flu vaccine in a late-stage…
[ad_1] A vial of the Moderna coronavirus booster vaccine targeting BA.4 and BA.5 Omicron subvariants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, Sept. 8, 2022. Hannah Beier | Reuters The Centers for Disease Control and Prevention on Tuesday recommended that all Americans ages 6 months and older receive updated Covid shots from Pfizer and…
[ad_1] A health-care worker prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at a vaccination clinic in the Peabody Institute Library in Peabody, Massachusetts, Jan. 26, 2022. Vanessa Leroy | Bloomberg | Getty Images The Food and Drug Administration on Monday approved updated Covid vaccines from Pfizer and Moderna, putting the shots on track to…
[ad_1] Artur Widak | Nurphoto | Getty Images Moderna‘s new Covid vaccine produced a strong immune response against BA.2.86, a highly mutated omicron variant that health officials are watching closely, according to clinical trial data the biotech company released Wednesday. The updated shot produced an 8.7-fold increase in protective antibodies against BA.2.86, which has been…
